Study of TNFalpha antagonists against neurosarcoidosis

Study of TNFalpha antagonists against neurosarcoidosis - Study of TNFalpha antagonists against neurosarcoidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025229

Enrollment

Registered

2016-12-12

Start date

2016-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuro-sarcoidosis

Interventions

Influiximab is administered intravenously at a dose of 3 mg per kg of body weight. It is administered at 2 weeks, 6 weeks after the first dose, and administered at intervals of 8 weeks thereafter.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: One specific example is the target.

Exclusion criteria

Exclusion criteria: One specific example is the target.

Design outcomes

Primary

Measure	Time frame
Recurrence of nerve sarcoidosis on spinal cord lesions.	—

Countries

Japan

Contacts

Public ContactNaoki Suzuki

Tohoku University Hospital, Department of Neurology

naoki@med.tohoku.ac.jp022-717-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026